Posts tagged as:

pharmaceuticals

FDA to review femur fractures connection

by certifiedbug on March 10, 2010

in News

FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures
03-10-2010

Patients and healthcare professionals may have questions about oral bisphosphonate medications and atypical subtrochanteric femur fractures – fractures in the bone just below the hip joint. Oral bisphosphonates are commonly prescribed to prevent or treat osteoporosis in postmenopausal women. Common brand names of medications in this class include Fosamax, Actonel, Boniva, and Reclast.

Recent news reports have raised the question about whether there is an increased risk of this type of fracture in patients with osteoporosis using these medications. At this point, the data that FDA has reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures. FDA is working closely with outside experts, including members of the recently convened American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force, to gather additional information that may provide more insight into this issue.

Meanwhile the FDA is recommending patients should not stop taking their medication unless told to do so by their healthcare professional.

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm

http://certifiedbug.com/blog/2010/03/09/osteoporosis-drugs-possible-effects-of-long-term-use/

Merck Responds to News Reports about FOSAMAX® (alendronate sodium) Tablets
http://merck.com/newsroom/company-statements/2010_0310.html

AAOS: American Academy of Orthopaedic Surgeons®: Quantity vs. quality: Long-term use of bone-building osteoporosis drugs

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

http://www6.aaos.org/news/pemr/releases/release.cfm?releasenum=877

{ 0 comments }

Osteoporosis drugs: possible effects of long term use

by certifiedbug on March 9, 2010

in News

Pharmaceutical company Merck’s patent on the Osteoporosis drug “Fosamax” expired in February 2008 leaving the gate open for generic drug makers to roll out low-cost versions.
The brand “Fosamax” is expensive, Merck & Co reported second quarter 2009 sales of $277 million for FOSAMAX alone. Presumably with generics available more people will be able to afford to fill a prescription but it might pay to do some homework first.

Last night ABC turned the spotlight on this class of drugs known as bisphosphonates.
World News: Long-term Use of Popular Class of Osteoporosis Drugs

Frozen Bone Syndrome+Fosamax, Esophagus Cancer+Fosamax, Heart+Fosamax, Jaw Death+Fosamax, Osteonecrosis of the Jaw+Fosamax typed into a search engine will return pages of hits.

Alix Spiegel, December 21, 2009. How A Bone Disease Grew To Fit The Prescription

New York Times, July 15, 2008. Drugs to Build Bones May Weaken Them

Australian Broadcasting Corporation, November 12, 2007. Concern over osteoporosis drug

FDA MedWatch Safety Alert, January 7, 2007. Severe Pain with Osteoporosis Drugs

July 29, 2009. Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw
http://www.merck.com/newsroom/news-release-archive/product/fosamax_statement.html

{ 0 comments }

FDA Warns Public of International extortion scam

January 4, 2010

FDA News Release
Dec. 29, 2009
FDA Warns Public of Continued Extortion Scam by FDA Impersonators
The U.S. Food and Drug Administration is warning the public about criminals posing as FDA special agents and other law enforcement personnel as part of an international extortion scam.
The criminals call the victims — who in most cases previously purchased drugs over [...]

Read the full article →

FDA Issues Warning Letters to Web site Operators

November 23, 2009

FDA NEWS RELEASE
The U.S. Food and Drug Administration today completed a coordinated, weeklong, international effort, called the International Internet Week of Action (IIWA), intended to curb illegal actions involving medical products.
During the effort, the FDA’s Office of Criminal Investigations (OCI), in conjunction with the Center for Drug Evaluation and Research and the Office of Regulatory [...]

Read the full article →

Fake pharmaceuticals on-line, buyer beware

March 30, 2007

With the cost of pharmaceuticals at an all time high, people turn to the internet for alternatives. While there are certainly legitimate licensed pharmacies on-line, the internet has become a haven for cheap, unapproved, outdated and illegal products that are being shipped to consumers.
According to reports in Canadian newspapers, Marcia Bergeron died from taking pills [...]

Read the full article →